Nebius Stock: Insider Sales, a Halved Price Target, and the 2027 Revenue Test Nobody Can Skip
Published on 11/18/2026 at 02:41 | Editorial boerse-global.deTwo directors sold Nebius shares while the stock was still reeling, and Wall Street spent the same week marking the company's valuation down to a far less flattering number. Director John Wilson Boynton IV offloaded 4,502 Class A shares on Friday. Sales chief Marc Boroditsky exercised 7,000 options on November 11 and sold the same number of Class A shares at a weighted average price of $147.97. Both moves were disclosed in mandatory filings.
The insider activity landed against a brutal stretch for the share price. Nebius closed yesterday down 1.1%, bringing its seven-day decline to 31%.
A blowout quarter that answers the wrong question
The company's third-quarter report, released Thursday, showed revenue of $980.8 million for Q3 2026 — growth of 571% year over year. That figure proves demand is real. What it does not prove is how reliably Nebius can convert its expanding footprint into booked sales.
On the same day, management said delays in third-party capacity would push part of its expected revenue into 2027. For shareholders, the realization of that deferred business is now the single variable that matters. The disclosure describes a shift in timing, not a guarantee that the money ever arrives.
Should investors sell immediately? Or is it worth buying Nebius?
Full-year 2026 revenue is now expected at the low end of the $3.0 billion to $3.4 billion range. That narrows the bar for the current year considerably. A durable re-rating, though, depends on something else: whether Nebius can put the cause of the slippage behind it. No analyst price target settles that — it is an operating question.
Capex climbs to $27 billion
The risk side of the ledger got heavier on Thursday. Nebius raised its 2026 capital expenditure forecast to roughly $27 billion, up from a prior range of $20 billion to $25 billion.
Higher spending sharpens the stakes on timing. The danger is not simply that revenue shows up late. It is the combination of a bigger bill and repeated delays — a scenario in which expectations for future business keep climbing while the operational proof stays missing.
Two brokers, two very different haircuts
The spread in analyst reaction illustrates how much conviction varies on the deferred revenue. Citigroup's Tyler Radke cut his target to $215 from $265 while keeping a buy rating, according to media reports. The combination says more than the number alone: Radke pulled back his valuation without abandoning his positive view on the investment case.
D.A. Davidson went further. Analyst Gil Luria halved his target to $125 from $250 on Friday, according to media reports, while leaving his rating at neutral. That call does not refute the growth potential. It does show the range of outcomes investors are pricing — the crux being how much confidence to place in revenue that has been promised for later.
Nebius at a turning point? This analysis reveals what investors need to know now.
What would settle the argument
A constructive case remains available. If the delays stay contained and Nebius meets its revised guidance, the deferred revenue could arrive without forcing investors to discard the underlying growth thesis. The 571% quarter would then read as evidence that short-term swings are not a permanent break.
The next concrete checkpoint is delivery on that low-end annual revenue target. Beyond it, the announced shift of revenue into 2027 becomes the decisive test. Should further slippage pile up, the reliability of the whole plan would weigh more heavily than the historical growth rate.
For investors, the direction will not be set by any single house's lower target. What counts is whether Nebius turns expected future receipts into reported sales. Only that proof would shrink the uncertainty hanging over the deferral.
Ad
Nebius Stock: New Analysis - 18 November
Fresh Nebius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
